Innovative Hospital-Wide Trial Demonstrates Cost-Effective Method for Comparing Intravenous Fluids

A pioneering clinical trial led by researchers at The Ottawa Hospital and the University of Ottawa showcases a highly efficient and powerful approach to comparing standard treatments across hospitals. Published in the New England Journal of Medicine, the study evaluates the use of hospital-wide, cluster-randomized methods for assessing intravenous fluids commonly used in clinical settings.

The trial specifically compared two widely used intravenous solutions: normal saline and Ringer's lactate. These fluids have been staples in hospitals for decades, yet there has been limited direct comparison of their effectiveness. Instead of traditional patient-by-patient randomization, the study assigned entire hospitals to use one fluid for three months, then switched to the other, streamlining the process.

This innovative design enabled the collection of data from over 43,000 patients across seven hospitals in Ontario, utilizing existing health administrative data directly. This method eliminated the need for individual patient recruitment, significantly speeding up data gathering and reducing costs. Despite the early termination of the study due to the COVID-19 pandemic, the findings demonstrated the potential of this approach for future research.

The researchers highlighted that this hospital-wide strategy cost less than $10 to enroll each patient, far less than traditional trials, which can exceed $1,000 per participant. The Ottawa Methods Center played a crucial role in designing this trial, aiming to facilitate similar studies that can efficiently answer critical medical questions.

Dr. Lauralyn McIntyre, the trial leader, emphasized the collective effort behind the study, praising hospital staff, healthcare professionals, and researchers for their cooperation. She expressed optimism that this model could be adopted for other comparative effectiveness research, contributing to better resource utilization and quicker procurement of evidence for clinical decision-making.

This research, which received ethical approval from the Ottawa Health Science Network, underscores the importance of innovative trial designs in advancing medical science and improving healthcare practices.